Literature DB >> 22414602

MicroRNA 96 is a post-transcriptional suppressor of anaplastic lymphoma kinase expression.

Deeksha Vishwamitra1, Yong Li, Desiree Wilson, Roxsan Manshouri, Choladda V Curry, Bin Shi, Xi Ming Tang, Andrea M Sheehan, Ignacio I Wistuba, Ping Shi, Hesham M Amin.   

Abstract

Anaplastic lymphoma kinase (ALK) constitutes a part of the oncogenic fusion proteins nucleophosmin-ALK and echinoderm microtubule-associated protein like 4-ALK, which are aberrantly expressed in a subset of T-cell anaplastic large-cell lymphoma and non-small-cell lung cancer, respectively. The expression of mutated, constitutively active ALK also occurs in a subset of neuroblastoma tumors. ALK is believed to play an important role in promoting tumor survival. Nevertheless, the mechanisms underlying the expression of ALK in cancer cells are not completely known. MicroRNA (miR) has been implicated in the regulation of the expression of both oncogenes and tumor suppressor genes. We tested the hypothesis that the expression of ALK could be regulated by miR. Three Internet-based algorithms identified miR-96 to potentially bind with the ALK 3'-untranslated region. Notably, miR-96 levels were markedly decreased in ALK-expressing cancer cell lines and primary human tumors compared with their normal cellular and tissue counterparts. Transfection of the cell lines with miR-96 decreased levels of the different forms of ALK protein, without significant effects on ALK mRNA. Furthermore, miR-96 decreased the phosphorylation of ALK target proteins, including Akt, STAT3, JNK, and type I insulin-like growth factor receptor, and it down-regulated JunB. These effects were associated with reduced proliferation, colony formation, and migration of ALK-expressing cancer cells. These data provide novel evidence that decreases in miR-96 could represent a mechanism underlying the aberrant expression of ALK in cancer cells.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22414602      PMCID: PMC3349824          DOI: 10.1016/j.ajpath.2012.01.008

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  34 in total

Review 1.  The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.

Authors:  Fergal C Kelleher; Ray McDermott
Journal:  Eur J Cancer       Date:  2010-05-05       Impact factor: 9.162

2.  Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34.

Authors:  Jason F Wiggins; Lynnsie Ruffino; Kevin Kelnar; Michael Omotola; Lubna Patrawala; David Brown; Andreas G Bader
Journal:  Cancer Res       Date:  2010-06-22       Impact factor: 12.701

3.  miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer.

Authors:  Shuangni Yu; Zhaohui Lu; Changzheng Liu; Yunxiao Meng; Yihui Ma; Wugan Zhao; Jianping Liu; Jia Yu; Jie Chen
Journal:  Cancer Res       Date:  2010-07-07       Impact factor: 12.701

4.  NPM-ALK inhibits the p53 tumor suppressor pathway in an MDM2 and JNK-dependent manner.

Authors:  Yu-Xin Cui; Alan Kerby; Fiona Kate Elizabeth McDuff; Hongtao Ye; Suzanne Dawn Turner
Journal:  Blood       Date:  2009-03-13       Impact factor: 22.113

5.  Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells.

Authors:  Irene K Guttilla; Bruce A White
Journal:  J Biol Chem       Date:  2009-07-01       Impact factor: 5.157

6.  IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells.

Authors:  Ping Shi; Raymond Lai; Quan Lin; Abid S Iqbal; Leah C Young; Larry W Kwak; Richard J Ford; Hesham M Amin
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

7.  Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.

Authors:  Isabelle Janoueix-Lerosey; Delphine Lequin; Laurence Brugières; Agnès Ribeiro; Loïc de Pontual; Valérie Combaret; Virginie Raynal; Alain Puisieux; Gudrun Schleiermacher; Gaëlle Pierron; Dominique Valteau-Couanet; Thierry Frebourg; Jean Michon; Stanislas Lyonnet; Jeanne Amiel; Olivier Delattre
Journal:  Nature       Date:  2008-10-16       Impact factor: 49.962

8.  Identification of ALK as a major familial neuroblastoma predisposition gene.

Authors:  Yaël P Mossé; Marci Laudenslager; Luca Longo; Kristina A Cole; Andrew Wood; Edward F Attiyeh; Michael J Laquaglia; Rachel Sennett; Jill E Lynch; Patrizia Perri; Geneviève Laureys; Frank Speleman; Cecilia Kim; Cuiping Hou; Hakon Hakonarson; Ali Torkamani; Nicholas J Schork; Garrett M Brodeur; Gian P Tonini; Eric Rappaport; Marcella Devoto; John M Maris
Journal:  Nature       Date:  2008-08-24       Impact factor: 49.962

9.  Mutations in the seed region of human miR-96 are responsible for nonsyndromic progressive hearing loss.

Authors:  Angeles Mencía; Silvia Modamio-Høybjør; Nick Redshaw; Matías Morín; Fernando Mayo-Merino; Leticia Olavarrieta; Luis A Aguirre; Ignacio del Castillo; Karen P Steel; Tamas Dalmay; Felipe Moreno; Miguel Angel Moreno-Pelayo
Journal:  Nat Genet       Date:  2009-04-12       Impact factor: 38.330

10.  Activating mutations in ALK provide a therapeutic target in neuroblastoma.

Authors:  Rani E George; Takaomi Sanda; Megan Hanna; Stefan Fröhling; William Luther; Jianming Zhang; Yebin Ahn; Wenjun Zhou; Wendy B London; Patrick McGrady; Liquan Xue; Sergey Zozulya; Vlad E Gregor; Thomas R Webb; Nathanael S Gray; D Gary Gilliland; Lisa Diller; Heidi Greulich; Stephan W Morris; Matthew Meyerson; A Thomas Look
Journal:  Nature       Date:  2008-10-16       Impact factor: 49.962

View more
  25 in total

1.  Long non-coding RNA MEG3 suppresses the development of bladder urothelial carcinoma by regulating miR-96 and TPM1.

Authors:  Guanghua Liu; Xin Zhao; Jingmin Zhou; Xiangming Cheng; Zixing Ye; Zhigang Ji
Journal:  Cancer Biol Ther       Date:  2018-11-21       Impact factor: 4.742

2.  MicroRNA-96 expression induced by low-dose cisplatin or doxorubicin regulates chemosensitivity, cell death and proliferation in gastric cancer SGC7901 cells by targeting FOXO1.

Authors:  Chunhui Lang; Miao Xu; Ziyi Zhao; Jinyao Chen; Lishi Zhang
Journal:  Oncol Lett       Date:  2018-07-11       Impact factor: 2.967

3.  Genome-wide screening identifies oncofetal lncRNA Ptn-dt promoting the proliferation of hepatocellular carcinoma cells by regulating the Ptn receptor.

Authors:  Jin-Feng Huang; Hong-Yue Jiang; Hui Cai; Yan Liu; Yi-Qing Zhu; Sha-Sha Lin; Ting-Ting Hu; Tian-Tian Wang; Wen-Jun Yang; Bang Xiao; Shu-Han Sun; Li-Ye Ma; Hui-Rong Yin; Fang Wang
Journal:  Oncogene       Date:  2019-01-14       Impact factor: 9.867

4.  The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.

Authors:  Raymond Lai; Robert J Ingham
Journal:  Ther Adv Hematol       Date:  2013-04

5.  NPM-ALK up-regulates iNOS expression through a STAT3/microRNA-26a-dependent mechanism.

Authors:  Haifeng Zhu; Deeksha Vishwamitra; Choladda V Curry; Roxsan Manshouri; Lixia Diao; Aarish Khan; Hesham M Amin
Journal:  J Pathol       Date:  2013-03-14       Impact factor: 7.996

Review 6.  Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.

Authors:  Bengt Hallberg; Ruth H Palmer
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

Review 7.  MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours.

Authors:  Michele Ghidini; Jens C Hahne; Melissa Frizziero; Gianluca Tomasello; Francesco Trevisani; Andrea Lampis; Rodolfo Passalacqua; Nicola Valeri
Journal:  Target Oncol       Date:  2018-08       Impact factor: 4.493

Review 8.  Anaplastic lymphoma kinase: Role in cancer and therapy perspective.

Authors:  Zhihong Zhao; Vivek Verma; Mutian Zhang
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 9.  Sensational MicroRNAs: Neurosensory Roles of the MicroRNA-183 Family.

Authors:  Samantha A Banks; Marsha L Pierce; Garrett A Soukup
Journal:  Mol Neurobiol       Date:  2019-07-29       Impact factor: 5.682

10.  miR-96 suppresses renal cell carcinoma invasion via downregulation of Ezrin expression.

Authors:  Nengwang Yu; Shuai Fu; Yubao Liu; Zhonghua Xu; Yi Liu; Junwen Hao; Baocheng Wang; Aimin Zhang
Journal:  J Exp Clin Cancer Res       Date:  2015-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.